Zhejiang Shouxiangu Pharmaceutical Co (603896) Fair Value & Analysis
Healthcare · CN · Market cap 3.1B CNY
Fair value as of: Jun 24, 2026
Analysis
Zhejiang Shouxiangu Pharmaceutical Co (603896) currently trades at ¥13.99, while our model-based Fair Value estimate is ¥6.27 — implying the stock looks roughly 55.2% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. engages in the selection, cultivation, processing, and sale of medicinal materials in China. It offers Ganoderma lucidum spore powder and brand broken cell wall powder, as well as broken wall Ganoderma lucidum spore powder granules and powder tablets; Tiepi Fengdou granules; and Tiepi Fengdou Ganoderma lucidum extracts. The company offers its products under the Shouxiangu brand. Zhejiang Shouxiangu Pharmaceutical Co., Ltd. was founded in 1997 and is headquartered in Jinhua, China.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Zhejiang Shouxiangu Pharmaceutical Co (603896) undervalued?
What is the fair value of 603896?
What is the quality score of 603896?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.